SEC charges Cassava Sciences, founder, and ex-VP $40M for misleading statements on Alzheimer's treatment trial, no admission of guilt.

The SEC has charged Cassava Sciences and two former executives for making misleading statements regarding a clinical trial for an Alzheimer's treatment. The company, along with founder Remi Barbier and ex-vice president Dr. Lindsay Burns, will pay over $40 million to settle the charges without admitting wrongdoing. The company has cooperated with the investigation and implemented corrective measures, allowing it to focus on ongoing clinical trials.

6 months ago
17 Articles